Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer.
Kuhl V, Clegg W, Meek S, Lenz L, Flake DD 2nd, Ronan T, Kornilov M, Horsch D, Scheer M, Farber D, Zalaznick H, Cussenot O, Compérat E, Cancel-Tassin G, Wild PJ, Chun FK, Mandel P, Moinfar F, Cohen T, Delee S, Kronenwett R, Doedt J. Kuhl V, et al. Among authors: flake dd 2nd. Biomark Med. 2022 Apr;16(6):449-459. doi: 10.2217/bmm-2021-0479. Epub 2022 Mar 24. Biomark Med. 2022. PMID: 35321552 Free article.
Hereditary cancer risk assessment and genetic testing in the community urology practice setting.
Shore ND, Lenz L, Cogan ES, Iliev D, Spencer L, Flake DD 2nd, Meek S, Davis T, Copeland K, Finch R, Schiff W, Korman H, Rao M, Belkoff L, Jalkut M, Mariados N, D'Anna R, Mehlhaff B, Slavin TP, Cohen TD. Shore ND, et al. Among authors: flake dd 2nd. Prostate. 2022 May;82(7):850-857. doi: 10.1002/pros.24327. Epub 2022 Mar 3. Prostate. 2022. PMID: 35239202
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.
Tward JD, Schlomm T, Bardot S, Canter DJ, Scroggins T, Freedland SJ, Lenz L, Flake DD 2nd, Cohen T, Brawer MK, Stone S, Bishoff J. Tward JD, et al. Among authors: flake dd 2nd. Clin Genitourin Cancer. 2021 Aug;19(4):296-304.e3. doi: 10.1016/j.clgc.2021.01.003. Epub 2021 Jan 19. Clin Genitourin Cancer. 2021. PMID: 33608228 Free article.
Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.
Curtis JR, Weinblatt ME, Shadick NA, Brahe CH, Østergaard M, Hetland ML, Saevarsdottir S, Horton M, Mabey B, Flake DD 2nd, Ben-Shachar R, Sasso EH, Huizinga TW. Curtis JR, et al. Among authors: flake dd 2nd. Arthritis Res Ther. 2021 Jan 4;23(1):1. doi: 10.1186/s13075-020-02389-4. Arthritis Res Ther. 2021. PMID: 33397438 Free PMC article.
Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.
Soliman H, Flake DD 2nd, Magliocco A, Robson M, Schwartzberg L, Sharma P, Brown K, Wehnelt S, Kronenwett R, Gutin A, Lancaster J, Cuzick J, Gradishar W. Soliman H, et al. Among authors: flake dd 2nd. JCO Precis Oncol. 2019 Aug 6;3:PO.18.00361. doi: 10.1200/PO.18.00361. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914026 Free PMC article.
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Soliman H, Wagner S, Flake DD 2nd, Robson M, Schwartzberg L, Sharma P, Magliocco A, Kronenwett R, Lancaster JM, Lanchbury JS, Gutin A, Gradishar W. Soliman H, et al. Among authors: flake dd 2nd. Ann Surg Oncol. 2020 Mar;27(3):765-771. doi: 10.1245/s10434-019-08039-7. Epub 2020 Jan 6. Ann Surg Oncol. 2020. PMID: 31907749 Free PMC article.
17 results